课题基金 / 基金详情

Integrative Chemical Biology of Neurodegeneration: Foundation to Novel Therapies

Integrative Chemical Biology of Neurodegeneration: Foundation to Novel Therapies
神经退行性变的综合化学生物学:新疗法的基础
批准号:
8044045
负责人:
Daniel Martin Watterson
金额:
$25.9万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2012-02-29

项目摘要

项目成果

Daniel Martin Watterson的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Our overall hypothesis is that restoration of up-regulated CNS proinflammatory cytokine production back towards homeostasis can provide attenuation of neurodegenerative disease progression. Specific to this proposal, we hypothesize that this common mechanism of pathophysiology progression can be targeted for decreasing neurodegeneration related to acute brain injury, injury related to chronic neurodegenerative disease, and the contribution of prior acute brain injury to increased susceptibility to the second injury. The three paradigms address disease progression in complex disorders, with the two-hit model addressing prior medical history contributions to later stage disease. The proposed research will use bioavailable, novel small molecule compounds developed in the principal investigator's laboratory to modulate the brain proinflammatory cytokine surge that contributes to hippocampal synaptic dysfunction. The in vivo brain injuries include an acute impact injury as a surrogate for traumatic brain injury (TBI), an Alzheimer's disease (AD)-relevant injury using toxic forms of human Abeta, and a two-hit injury model of TBI followed by a later AD-relevant injury. The pathophysiology progression endpoints include proinflammatory cytokine levels, and the neurological outcomes endpoints include changes in synaptic marker proteins and hippocampus-dependent behavior changes. The two-hit injury studies are a way to explore initially the neglected question of how a prior brain injury can be a susceptibility factor for age-onset AD and other neurological disorders, and to directly address the potential for developing new therapies that alter short and long term outcomes of brain injury on later neurological disease susceptibility, onset and progression. The ability of bioavailable small molecules that attenuate the up-regulation of brain proinflammatory cytokine levels and modulate the neurological outcomes of brain injuries will provide an integrative chemical biology demonstration of the causal relationships between this common pathophysiology mechanism and brain dysfunctions. Successful completion of the proposed studies will provide a firm foundation for future clinical investigations that seek to translate a large body of public health data into potential therapeutic intervention paradigms, and provide an immediate stimulus to ongoing clinical development of new classes of potential disease-modifying therapeutics. PUBLIC HEALTH RELEVANCE: Successful completion of the proposed studies will provide a foundation for immediate translation of basic science into potential disease-modifying clinical interventions using new classes of therapeutics.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1371/journal.pone.0014120
发表时间: 2010-11-30
期刊: PloS one
影响因子: 3.7
作者: [Zimmermann M, Atmanene C, Xu Q, Fouillen L, Van Dorsselaer A, Bonnet D, Marsol C, Hibert M, Sanglier-Cianferani S, Pigault C, McNamara LK, Watterson DM, Haiech J, Kilhoffer MC]
通讯作者: Kilhoffer MC
Site-directed mutagenesis of the glycine-rich loop of death associated protein kinase (DAPK) identifies it as a key structure for catalytic activity.
对富含甘氨酸的死亡环相关蛋白激酶 (DAPK) 进行定点诱变,将其确定为催化活性的关键结构。
DOI: 10.1016/j.bbamcr.2010.11.011
发表时间: 2011
期刊: Biochimica et biophysica acta
影响因子: --
作者: [McNamara,LaurieK, Brunzelle,JosephS, Schavocky,JamesP, Watterson,DMartin, Grum-Tokars,Valerie]
通讯作者: Grum-Tokars,Valerie
Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate
  • 批准号:
    9902252
  • 项目类别:
  • 资助金额:
    $201.87万
  • 财政年份:
    2018
  • 负责人:
    Daniel Martin Watterson
  • 依托单位:
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors
  • 批准号:
    8422736
  • 项目类别:
  • 资助金额:
    $95.82万
  • 财政年份:
    2012
  • 负责人:
    Daniel Martin Watterson
  • 依托单位:
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors
  • 批准号:
    8724322
  • 项目类别:
  • 资助金额:
    $114.17万
  • 财政年份:
    2012
  • 负责人:
    Daniel Martin Watterson
  • 依托单位:
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors
  • 批准号:
    8549070
  • 项目类别:
  • 资助金额:
    $90.28万
  • 财政年份:
    2012
  • 负责人:
    Daniel Martin Watterson
  • 依托单位: